View On Demand

InflammX Expands Its Scope To Include Diabetic Kidney Disease

About the Event

Diabetes is one of the most common chronic illnesses in the United States, affecting over 34.2 million people. Two major complications associated with diabetes are kidney disease and retinal disease in the eyes and both are caused by inflammation of the microvasculature.

InflammX Therapeutics has developed Xiflam, a once daily pill that’s proven effective in regulating out of control inflammation in both the eyes and liver. In a recent test in small animals that were born with diabetes and had significant impairment of visual function at 4 weeks, Xiflam reduced inflammation, resolved the microvascular pathology, and significantly restored visual function.

Join this webinar to hear InflammX CEO, Dr. Brian Levy share details of this very promising development in the treatment of two of the most common and devastating side effects of diabetes.

View On-Demand Webinar


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.